B1Q
NRx Pharmaceuticals, Inc., a clinical-stage bio-pharmaceutical company, develops novel therapeutics for the treatment of central nervous system disorders comprising suicidal depression, post-traumatic stress disorder, and chronic pain. Its lead drug candidates include NRX-101, an oral, fixed dosed combination of D-cycloserine and lurasidone for suicidal treatment-resistant bipolar depression in p… Read more
Market Cap & Net Worth: B1Q (B1Q)
B1Q (F:B1Q) has a market capitalization of $51.36 Million (€50.03 Million) as of March 19, 2026. Listed on the F stock exchange, this Germany-based company holds position #22784 globally and #2475 in its home market, demonstrating a 19.86% increase in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying B1Q's stock price €1.69 by its total outstanding shares 29605150 (29.61 Million).
B1Q Market Cap History: 2026 to 2026
B1Q's market capitalization history from 2026 to 2026. Data shows growth from $51.36 Million to $51.36 Million (0.00% CAGR).
B1Q Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how B1Q's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance.
Latest Price to Sales (P/S) Ratio
No P/S ratio data available
Latest Price to Earnings (P/E) Ratio
No P/E ratio data available
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| No financial ratio data available | |||||
Competitor Companies of B1Q by Market Capitalization
Companies near B1Q in the global market cap rankings as of March 19, 2026.
Key companies related to B1Q by market ranking:
- Vertex Pharmaceuticals Inc (NASDAQ:VRTX): Ranked #162 globally with a market cap of $117.09 Billion USD.
- Regeneron Pharmaceuticals Inc (NASDAQ:REGN): Ranked #281 globally with a market cap of $74.80 Billion USD.
- CSL Limited (PINK:CMXHF): Ranked #344 globally with a market cap of $63.46 Billion USD.
- argenx SE (OTCGREY:ARGNF): Ranked #500 globally with a market cap of $42.99 Billion USD.
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #162 | Vertex Pharmaceuticals Inc | NASDAQ:VRTX | $117.09 Billion | $462.49 |
| #281 | Regeneron Pharmaceuticals Inc | NASDAQ:REGN | $74.80 Billion | $759.05 |
| #344 | CSL Limited | PINK:CMXHF | $63.46 Billion | $149.87 |
| #500 | argenx SE | OTCGREY:ARGNF | $42.99 Billion | $697.42 |
B1Q Historical Marketcap From 2026 to 2026
Between 2026 and today, B1Q's market cap moved from $51.36 Million to $ 51.36 Million, with a yearly change of 0.00%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | €51.36 Million | -- |
End of Day Market Cap According to Different Sources
On Mar 18th, 2026 the market cap of B1Q was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $51.36 Million USD |
| MoneyControl | $51.36 Million USD |
| MarketWatch | $51.36 Million USD |
| marketcap.company | $51.36 Million USD |
| Reuters | $51.36 Million USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.